Comparative Pharmacology
Head-to-head clinical analysis: DARVOCET N 100 versus STADOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVOCET N 100 versus STADOL.
DARVOCET-N 100 vs STADOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a weak opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing prostaglandin synthesis and providing analgesia.
Partial agonist at mu-opioid receptors and agonist at kappa-opioid receptors in the CNS, altering pain perception and emotional response to pain.
Darvocet-N 100 contains propoxyphene napsylate 100 mg and acetaminophen 650 mg. For moderate to moderately severe pain, the typical adult dose is 1 tablet orally every 4 hours as needed. Maximum: 6 tablets per day (600 mg propoxyphene napsylate, 3900 mg acetaminophen).
Butorphanol tartrate 1-2 mg IV or IM every 3-4 hours as needed for pain; alternatively, 0.5-1 mg IV every 3-4 hours. For nasal spray: 1 mg (one spray) in one nostril, may repeat in 60-90 minutes if needed; then 1 mg every 3-4 hours as needed.
None Documented
None Documented
Propoxyphene: 6-12 hours (prolonged in elderly and hepatic impairment); norpropoxyphene metabolite: 30-36 hours. Acetaminophen: 1.5-3 hours.
Terminal elimination half-life: 2.5-4 hours; clinically, prolonged in hepatic impairment (up to 10-12 hours) and elderly
Propoxyphene: primarily hepatic metabolism to norpropoxyphene, renal excretion of metabolites (20-25% unchanged propoxyphene). Acetaminophen: renal excretion of glucuronide and sulfate conjugates (90-95% total), 2-4% unchanged.
Renal: 85-90% as unchanged drug and metabolites (primarily as glucuronide conjugates); Fecal: <10%; Biliary: minimal
Category C
Category C
Opioid Analgesic
Opioid Analgesic